Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 625, Issue 1-3, Pages 73-83Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2009.08.044
Keywords
Apoptotic agent; Chemoattractance; Growth arrest; Immune escape; Metastasis; Reactive oxygen species; Stress response; Tumorgenesis
Categories
Funding
- CLA/GSK/CIHR
- CIHR National Training Program
- NIH [RO1 GM62112]
- Deutsche Forschungsgemeinschaft (DFG) [KE 820/2-4, KE 820/6-1]
- Canada Research Chairs Program
Ask authors/readers for more resources
Correlations exist between the abundance of S100 proteins and disease pathologies. Indeed, this is evidenced by the heterodimeric S100 protein complex S100A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. However, S100A8/A9 appears as a Janus-faced molecule in this context. On the one hand, it is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S100A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Clearly, there is a dichotomy and future investigations into the role of S100A8/A9 in cancer biology need to consider both sides of the same coin. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available